- Home
- IFRX vs ABOS Comparison
IFRX vs ABOS Comparison
Compare IFRX & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- ABOS
- Stock Information
- Founded
- IFRX 2007
- ABOS 1996
- Country
- IFRX Germany
- ABOS United States
- Employees
- IFRX N/A
- ABOS N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- IFRX Health Care
- ABOS Health Care
- Exchange
- IFRX Nasdaq
- ABOS Nasdaq
- Market Cap
- IFRX 65.8M
- ABOS 76.9M
- IPO Year
- IFRX 2017
- ABOS 2021
- Fundamental
- Price
- IFRX $1.30
- ABOS $1.08
- Analyst Decision
- IFRX Strong Buy
- ABOS Strong Buy
- Analyst Count
- IFRX 2
- ABOS 3
- Target Price
- IFRX $9.00
- ABOS $7.33
- AVG Volume (30 Days)
- IFRX 322.6K
- ABOS 268.9K
- Earning Date
- IFRX 05-07-2025
- ABOS 05-13-2025
- Dividend Yield
- IFRX N/A
- ABOS N/A
- EPS Growth
- IFRX N/A
- ABOS N/A
- EPS
- IFRX N/A
- ABOS N/A
- Revenue
- IFRX $171,642.00
- ABOS N/A
- Revenue This Year
- IFRX $106.72
- ABOS N/A
- Revenue Next Year
- IFRX $66.89
- ABOS N/A
- P/E Ratio
- IFRX N/A
- ABOS N/A
- Revenue Growth
- IFRX 162.79
- ABOS N/A
- 52 Week Low
- IFRX $0.82
- ABOS $0.86
- 52 Week High
- IFRX $2.82
- ABOS $3.92
- Technical
- Relative Strength Index (RSI)
- IFRX 58.32
- ABOS 48.99
- Support Level
- IFRX $0.82
- ABOS $0.95
- Resistance Level
- IFRX $1.12
- ABOS $1.13
- Average True Range (ATR)
- IFRX 0.13
- ABOS 0.13
- MACD
- IFRX 0.06
- ABOS 0.02
- Stochastic Oscillator
- IFRX 90.49
- ABOS 71.43
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.